73-89kDa (Reducing)
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
Kawakami K, Kawakami M, Puri R. Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease. Mol Cancer Ther. 2004; 3:137–147. Valverde A, Povedano E, Montiel V, Yanez-Sedeno P, Garranzo-Asensio M, Barderas R, Campuzano S, Pingarron J. Electrochemical immunosensor for IL-13 Receptor alpha2 determination and discrimination of metastatic colon cancer cells. Biosens Bioelectron. 2018; 117:766–772. Okamoto H, Yoshimatsu Y, Tomizawa T, Kunita A, Takayama R, Morikawa T, Komura D, Takahashi K, Oshima T, Sato M, Komai M, Podyma-Inoue K, Uchida H, Hamada H, Fujiu K, Ishikawa S, Fukayama M, Fukuhara T, Watabe T. Interleukin-13 receptor alpha2 is a novel marker and potential therapeutic target for human melanoma. Sci Rep. 2019; 9:1281. Husain S, Puri R. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol. 2003; 65:37–48. Tu M, Wange W, Cai L, Zhu P, Gao Z, Zheng W. IL-13 receptor alpha2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway. Tumour Biol. 2016; 37:14701–14709. D.D. Donaldson, M.J. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J. Immunol., 161 (1998), pp. 2317-2324
Interleukin-13 receptor subunit alpha-2 (IL13RA2) is a high-affinity membrane receptor of IL-13 and is abundantly expressed in a variety of tumors, such as pancreatic cancer, ovarian cancer, breast cancer, colon cancer and melanoma. IL13RA2 is a glycosylated protein containing four potential glycosylation sites. IL13RA2 was initially considered a second, decoy receptor for interleukin 13 (IL-13). IL13RA2 is upregulated during helminthic and parasitic infections (i.e. schistosomiasis) as IgE is a key molecule in the fight against parasites and IL-13 is required for the IgE switching. A IL13RA2, an immunotherapeutic target, is considered a promising direction for the treatment of glioma.
1μg (R: reducing condition, N: non-reducing condition).
Immobilized IL-13 Protein, Cynomolgus (Cat. No. UA040112) at 2.0μg/mL (100μL/well) can bind IL13RA2/IL13R Fc Chimera, Human (Cat. No. UA010794) with EC50 of 0.14-0.22μg/mL.
您现在的位置：